2-溴-3-羟基苯甲酸 | 91658-91-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-3-羟基苯甲酸
• 英文名称: 2-bromo-3-hydroxybenzoic acid
• CAS: 91658-91-2
• 化学式: C₇H₅BrO₃
• 分子量: 217.019
• InChiKey: GBPZLKQDSNPABG-UHFFFAOYSA-N

物化性质

• 熔点：
  160-161 °C
• 沸点：
  335.1±32.0 °C(Predicted)
• 密度：
  1.861±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918290000
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  2-溴-3-羟基苯甲酸 在 sodium sulfite 作用下， 以 水 为溶剂， 反应 3.0h， 以85%的产率得到间羟基苯甲酸
  参考文献：
  名称：

  在水介质中用亚硫酸钠对苯酚和杂芳族化合物进行还原脱卤和脱卤磺化

  摘要：

  质子互变异构被用作在水介质中使用亚硫酸钠作为唯一试剂的（杂）芳基溴化物和碘化物的还原性脱卤化或（杂）芳基氯和氟化物的脱卤化磺化的工具。该方案不需要金属或相转移催化剂，避免使用有机溶剂作为反应介质。此方法特别适用于容易互变异构的底物（例如2-或4-卤代氨基酚和4-卤代间苯二酚），在温和的反应条件下（≤60°C）会进行脱卤或磺化。由于亚硫酸钠是一种廉价，安全且对环境无害的试剂，因此该方法至少具有三个潜在应用：（i）使用亚硫酸钠作为还原剂对卤素作为保护基进行脱保护；（ii）在温和的反应条件下磺化芳族卤化物，避免使用危险和腐蚀性的试剂/溶剂；（iii）将有毒的卤代芳族化合物转化为危害较小的化合物。

  DOI：

  10.1039/c9gc00467j
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 copper(I) bromide 作用下， 生成 2-溴-3-羟基苯甲酸
  参考文献：
  名称：

  Anesthetic considerations in a patient with visceral leishmaniasis

  摘要：

  Purpose: To describe the anesthetic problems in a patient with visceral leishmaniasis undergoing general anesthesia.Clinical features: A 17-yr-old man with visceral leishmaniasis was booked for emergency appendectomy. He received parentral sodium stibogluconate 600 mg per day. The patient was pale, afebrile and had hepatosplenomegaly. Preoperative investigations showed a hemoglobin of 6.2 g(.)dL (1), platelet count of 80 x 10(9.)L(-1) and serum albumin of 2.1 g(.)dL(-1). The electrocardiogram and chest x-ray were normal. Anesthesia was induced with 100 mug fentanyl and 50 mg propofol iv and tracheal intubation was facilitated with 3 mg vecuronium iv. Maintenance of anesthesia was done with intermittent positive pressure ventilation using 50% nitrous oxide and 0.4% isoflurane in oxygen. Reversal of neuromuscular blockade was achieved with 1.0 mg neostigmine and 0.2 mg atropine iv. 50 mg tramadol iv every six hours was used for postoperative analgesia. The perioperative course was uneventful.Conclusion: Patients with visceral leishmaniasis have problems unique to them that may influence the anesthetic management. Of particular concern to an anesthesiologist are the presence of hematological abnormalities (anemia, leukopenia, thrombocytopenia), and hypoalbuminic malnutrition. The combination of low hemoglobin and thrombocytopenia may necessitate blood component therapy perioperatively. Drugs affecting coagulation should be used judiciously. Hypoalbuminemia may adversely affect the pharmacokinetics of agents that are highly protein bound. The anesthetic management in a patient with visceral leishmaniasis may be further complicated by the presence of coexisting infections like pneumonia and tuberculosis. Leishmaniasis is a recognized complication of infection with human immunodeficiency virus.

  DOI：

  10.1007/bf03016827

文献信息

• [EN] ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS<br/>[FR] ACTIVATEUR D'INHIBITEURS DE L'HOMOLOGUE 2 DE ZESTE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2014195919A1

  公开（公告）日：2014-12-11

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

  这项发明涉及到按照式（I）的新化合物，这些化合物是增强子Zeste同源物2（EZH2）的抑制剂，以及含有它们的药物组合物，它们的制备方法，以及它们在治疗癌症方面的用途。
• Structure–activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: modification of P2 site
  作者：E Takashiro

  DOI：10.1016/s0968-0896(98)00004-2

  日期：1998.5

  The structure-activity relationship of HIV-1 protease (HIV-1 PR) inhibitors containing AHPBA (3-amino-2-hydroxy-4-phenylbutanoic acid) is discussed. In order to solve the problem of poor oral bioavailability, small-sized dipeptide HIV-1 protease inhibitors containing cyclic urethanes or benzamides at the P2 site were designed and prepared. The substitution patterns of the benzamides contributed significantly

  讨论了含有AHPBA（3-氨基-2-羟基-4-苯基丁酸）的HIV-1蛋白酶（HIV-1 PR）抑制剂的构效关系。为了解决口服生物利用度差的问题，设计并制备了在P2位点含有环状氨基甲酸酯或苯甲酰胺的小型二肽HIV-1蛋白酶抑制剂。苯甲酰胺的取代模式对其HIV-1 PR抑制活性有显着贡献，并且表明P2残基的选择非常重要。已经鉴定出具有亚纳摩尔IC 50值并且表现出良好的抗病毒效力的高效抑制剂。在该类别中，抑制剂18最有效（IC90（CEM / HIV-1 IIIB）0.11 microM），在狗中显示出良好的口服生物利用度。
• Optimized liquid-phase oxidation
  申请人：Wonders George Alan

  公开号：US20060047145A1

  公开（公告）日：2006-03-02

  Disclosed is an optimized process and apparatus for more efficiently and economically carrying out the liquid-phase oxidation of an oxidizable compound. Such liquid-phase oxidation is carried out in a bubble column reactor that provides for a highly efficient reaction at relatively low temperatures. When the oxidized compound is para-xylene and the product from the oxidation reaction is crude terephthalic acid (CTA), such CTA product can be purified and separated by more economical techniques than could be employed if the CTA were formed by a conventional high-temperature oxidation process.

  公开了一种优化的工艺和装置，用于更有效和经济地进行可氧化化合物的液相氧化。这种液相氧化是在气泡柱反应器中进行的，可以在相对较低的温度下提供高效的反应。当被氧化的化合物是对二甲苯，氧化反应的产物是粗对苯二甲酸（CTA）时，这种CTA产物可以通过比传统高温氧化工艺更经济的技术进行纯化和分离。
• DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
  申请人：GENFIT

  公开号：US20150038503A1

  公开（公告）日：2015-02-05

  The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.

  本发明提供了新型的6-取代[1,2,4]三唑并[4,3-b]吡啶嗪，这些化合物是Rev-Erb激动剂。这些化合物及其含有的药物组合物是治疗任何需要Rev-Erb激活具有治疗效果的疾病的适当手段，例如炎症和昼夜节律相关疾病或心脏代谢疾病。
• ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

  公开号：US20160122342A1

  公开（公告）日：2016-05-05

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

  本发明涉及一种新的化合物，其符合式(I)，其为增强子酶同源物2 (EZH2)的抑制剂，以及包含它们的制药组合物，其制备过程以及它们在治疗癌症方面的用途。